Micron Biomedical, Inc. Market Research Report

Background

Company Overview

Micron Biomedical, Inc. is a clinical-stage life science company specializing in the development of dissolvable microarray-based technologies for the needle-free delivery of drugs and vaccines. Founded in 2014 and headquartered in Atlanta, Georgia, the company aims to enhance global health outcomes by providing painless, self-administered, and thermostable alternatives to traditional injectable therapies.

Mission and Vision

Micron Biomedical's mission is to radically expand access to treatments and vaccines, improving global health outcomes by transforming how vaccines and drugs are administered. The company's vision is to simplify and advance the delivery and administration of drugs and vaccines through innovative, needle-free technologies.

Primary Area of Focus

The company's primary focus is on developing dissolvable microarray patches that enable needle-free, painless, and thermostable delivery of vaccines and therapeutics. This technology aims to eliminate the need for cold chain logistics and reduce infrastructure barriers, thereby improving patient compliance and access to essential medicines.

Industry Significance

Micron Biomedical is at the forefront of a transformative approach in the biopharmaceutical industry, addressing significant challenges related to vaccine distribution, storage, and administration. By offering a needle-free alternative, the company has the potential to enhance global immunization efforts, particularly in low- and middle-income countries where access to traditional injectable vaccines is limited.

Key Strategic Focus

Core Objectives

Global Health Impact: Expand access to life-saving vaccines and therapeutics, particularly in underserved regions.

Technological Innovation: Advance the development and commercialization of dissolvable microarray-based delivery systems.

Regulatory Advancement: Achieve regulatory approvals for needle-free vaccine and therapeutic products.

Specific Areas of Specialization

Needle-Free Vaccine Delivery: Developing microarray patches for vaccines such as measles-rubella and rotavirus.

Therapeutic Applications: Expanding the use of microarray technology for the delivery of various therapeutics.

Key Technologies Utilized

Dissolvable Microarray Technology: A proprietary system that allows for painless, self-administered delivery of drugs and vaccines without the need for needles or refrigeration.

Primary Markets Targeted

Global Health Organizations: Collaborations with entities like the Bill & Melinda Gates Foundation and the Centers for Disease Control and Prevention (CDC).

Low- and Middle-Income Countries: Focusing on regions with limited access to traditional injectable vaccines.

Developed Markets: Addressing vaccine hesitancy and improving patient compliance in higher-income countries.

Financials and Funding

Total Funds Raised

As of January 2025, Micron Biomedical has raised over $33 million in Series A financing.

Recent Funding Rounds

Series A Financing (November 2022): Raised $14 million, led by Global Health Investment Corporation (GHIC) and LTS Lohmann, with participation from GRA Venture Fund.

Series A Extension (May 2023): Secured an additional $3 million from J2 Ventures, bringing the total Series A funding to $17 million.

Series A3 Financing (January 2025): Announced a $16 million extension round led by J2 Ventures and GHIC, increasing the total Series A equity raise to over $33 million.

Notable Investors

J2 Ventures: Participated in the Series A extension and A3 financing rounds.

Global Health Investment Corporation (GHIC): Led the initial Series A financing and participated in subsequent rounds.

LTS Lohmann: Participated in the Series A financing.

GRA Venture Fund: Participated in the Series A financing.

Intended Utilization of Capital

The funds are allocated towards scaling up manufacturing capabilities, advancing clinical trials, and accelerating the commercialization of needle-free vaccines and therapeutics.

Pipeline Development

Key Pipeline Candidates

Measles-Rubella Vaccine: Developing a needle-free version using microarray technology, with positive Phase I/II data published.

Rotavirus Vaccine (CC24): Conducting first-in-human clinical trials in collaboration with Emory University and the CDC.

Influenza Vaccine: Collaborating with Zipcode Bio to develop an mRNA-based, needle-free flu vaccine, supported by a $2 million BARDA award.

Stages of Clinical Trials

Measles-Rubella Vaccine: Completed Phase I/II trials with positive results.

Rotavirus Vaccine: Ongoing first-in-human clinical trials.

Influenza Vaccine: Preclinical development, with plans for clinical trials pending.

Target Conditions

Measles-Rubella Vaccine: Preventing measles and rubella infections.

Rotavirus Vaccine: Preventing rotavirus-induced gastroenteritis.

Influenza Vaccine: Preventing seasonal influenza infections.

Anticipated Milestones

Measles-Rubella Vaccine: Regulatory submissions and commercialization in target markets.

Rotavirus Vaccine: Completion of clinical trials and regulatory approvals.

Influenza Vaccine: Initiation of clinical trials and subsequent commercialization.

Technological Platform and Innovation

Proprietary Technologies

Dissolvable Microarray Technology: Enables painless, self-administered delivery of drugs and vaccines without the need for needles or refrigeration.

Significant Scientific Methods

Microarray Patch Design and Development: Innovative design of microarray patches for efficient drug and vaccine delivery.

Clinical Trial Design: Conducting clinical trials to validate the safety and efficacy of needle-free vaccines and therapeutics.

Leadership Team

Steven Damon, PhD – CEO

An industry veteran with over 25 years of experience in the medical device and pharmaceutical industries. Former President and CEO of 4P Therapeutics, with executive roles in mergers & acquisitions, business development, and commercial development.

Devin McAllister, PhD – EVP, Chief Technology Officer, Co-founder

With 25 years of experience in medical device and pharmaceutical development, Dr. McAllister leads Micron’s R&D activities. He co-invented V-Go, the first insulin pump marketed to the Type 2 diabetes market.

Sebastien Henry, MS, MBA – EVP, Head of Technical Operations, Co-founder

Brings over 20 years of experience in microneedle and medical device fields. Previously worked at Porex Surgical and Georgia Tech, with multiple patents in microneedle technology.

Dr. Seth Berkley – Scientific Advisor

A global health pioneer and CEO of GAVI, the Vaccine Alliance, providing strategic guidance on vaccine development and global health initiatives.

Dr. Sandeep Patel – Advisor

Former Director of BARDA's Division of Research, Innovation and Ventures (DRIVe), bringing expertise in public health innovation to advance commercialization efforts.

Competitor Profile

Market Insights and Dynamics

The global vaccine delivery market is evolving, with a growing emphasis on needle-free technologies to improve patient compliance and access. Micron Biomedical's innovative approach positions it as a leader in this emerging market segment.

Competitor Analysis